Home Molecular Dx RNA

RNA

Latest
Substantia nigra in Parkinson's disease, illustration
RNA

Scripps Team Use mRNA to Target Protein Implicated in Parkinson’s Disease

Photo Madical Retina Abnormal isolated on black background.Retina of diabetes diabates retinopathy.
RNA

Retinopathy Gene Signature Predicts Breast Cancer Survival

Researchers at The University of Texas MD Anderson Cancer Center have found that a rare resistance mutation first thought to appear in melanoma (pictured) following treatment with a targeted therapy has instead turned out to be hiding in the tumor all along. [Definiens]
RNA

Melanoma Diagnosis Could be More Precise Using miRNA Biomarkers

RNA

Myriad Partners with LCPMH to Assess Clinical Utility of Prolaris Prostate...

RNA

Mammoth Milestone: CRISPR-Based Dx Developer Licenses 2 U. of California Patents

RNA

Oxford Nanopore Opens Factory to Meet Demand for MinION, Other DNA/RNA...

dementia
RNA

RNA Splicing Mutations Alter Tau Protein Isoforms in Alzheimer’s and Parkinson’s

GenomeDx Biosciences has agreed to pay the U.S. federal government $1.99 million to settle allegations that it submitted false claims to Medicare for the Decipher post-operative genetic test for prostate cancer patients. [National Cancer Institute
RNA

GenomeDx to Pay $1.99M to Settle Medicare Billing Allegations

Source: ROGER HARRIS/SCIENCE PHOTO LIBRARY/Getty Images
RNA

Better View of Microbiome Delivered by New tRNA Sequencing Technique

Messenger RNA (mRNA) therapy developer Moderna has raised at least $604.3 million in gross proceeds in the largest initial public offering for a biotech. [© Argus/Fotolia]
RNA

mRNA Therapy Developer Moderna Raises $604M in Largest-Ever Biotech IPO

Load more

New Products

View More
Load more
Copyright © 2020 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up